This is a major catalyst for CorMedix, as a successful expansion into prophylaxis could dramatically increase REZZAYO's commercial potential. Traders should monitor the upcoming pre-NDA meeting with the FDA and the planned sNDA submission in 2H26 for further validation of the data and regulatory pathway. The current analyst consensus (92% bullish) is now strongly supported by this positive clinical data.
Price Chart
Executive Summary
CorMedix announced positive topline results from its Phase III ReSPECT trial for REZZAYO (rezafungin) as prophylaxis against invasive fungal infections in high-risk transplant patients. The study met its primary endpoint of non-inferiority in fungal-free survival at Day 90 (60.7% for rezafungin vs. 59.0% for standard therapy) and showed favorable safety outcomes in secondary endpoints, including fewer toxicity-related discontinuations and drug-drug interactions. The company plans to submit a supplemental New Drug Application (sNDA) to the FDA in the second half of 2026.
Key Facts
- Phase III ReSPECT trial met primary endpoint of non-inferiority in fungal-free survival at Day 90: 60.7% for rezafungin vs. 59.0% for standard antimicrobial regimen.
- Rezafungin demonstrated a favorable safety profile with benefits in secondary endpoints, including fewer treatment-emergent adverse events leading to discontinuation.
- The trial was sponsored by Mundipharma, which holds commercial rights outside the U.S.; Melinta Therapeutics (a CorMedix subsidiary) will handle U.S. distribution.
- CorMedix and partners anticipate a pre-NDA meeting with the FDA in the coming months, with a target sNDA submission in 2H26.
- The U.S. market opportunity for REZZAYO in prophylaxis is estimated to exceed $2 billion, with U.S. patent coverage extending to 2038.
Financial Impact
The successful Phase III trial significantly increases the probability of regulatory approval and commercialization, potentially unlocking a U.S. market opportunity exceeding $2 billion. This represents a major expansion beyond its current approval for treatment of candidemia and invasive candidiasis.
Risk Factors
- The FDA may require additional data or raise concerns during the review process, potentially delaying or blocking approval.
- The commercial success of REZZAYO in prophylaxis will depend on market adoption, reimbursement, and competition from existing antifungal agents.
- The company may need to raise additional capital to fund the commercial launch, which could lead to shareholder dilution.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-047748 |
| Document: ea028764001ex99-1.htm | 0001213900-26-047748 |
| Document: 0001213900-26-047748-index-headers.html | 0001213900-26-047748 |
| Document: 0001213900-26-047748-index.html | 0001213900-26-047748 |
| Document: 0001213900-26-047748.txt | 0001213900-26-047748 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 13, 2026 7w ago | 8-K | $8.14 $7.83 | ▼ −3.87% | ▼ −2.12% | $7.19 (−11.67%) |
Aug 13, 2026 7w ago | Press Release | $8.14 $7.83 | ▼ −3.87% | ▼ −2.12% | $7.19 (−11.67%) |
Jul 1, 2026 13w ago | 8-K | $8.47 $7.19 | ▼ −15.11% | ▼ −12.93% | $7.19 (−15.11%) |
Jun 12, 2026 16w ago | Institutional Cluster | $8.74 $8.40 | ▼ −3.89% | ▼ −5.67% | $7.19 (−17.73%) |
Jun 8, 2026 16w ago | 8-K | $8.54 $8.79 | ▲ +2.93% | ▲ +1.30% | $7.19 (−15.81%) |
Jun 8, 2026 16w ago | Press Release | $8.54 $8.79 | ▲ +2.93% | ▲ +1.30% | $7.19 (−15.81%) |
May 14, 2026 20w ago | 8-K | $7.93 $8.74 | ▲ +10.21% | ▲ +11.07% | $7.19 (−9.33%) |
May 14, 2026 20w ago | Press Release | $7.93 $8.74 | ▲ +10.21% | ▲ +11.07% | $7.19 (−9.33%) |
Apr 27, 2026 22w ago | 8-K | $7.82 $8.27 | ▲ +5.75% | ▲ +0.80% | $7.19 (−8.06%) |
Apr 27, 2026 22w ago | Press Release | $7.82 $8.27 | ▲ +5.75% | ▲ +0.80% | $7.19 (−8.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access